<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7988931</article-id><article-id pub-id-type="publisher-id">8033</article-id><article-id pub-id-type="doi">10.1186/s12885-021-08033-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Pinato</surname><given-names>David J.</given-names></name><address><email>david.pinato@imperial.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cortellini</surname><given-names>Alessio</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sukumaran</surname><given-names>Ajithkumar</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Cole</surname><given-names>Tom</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Pai</surname><given-names>Madhava</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Habib</surname><given-names>Nagy</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Spalding</surname><given-names>Duncan</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Sodergren</surname><given-names>Mikael H.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Martinez</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dhillon</surname><given-names>Tony</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Tait</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ward</surname><given-names>Caroline</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kocher</surname><given-names>Hemant</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Yip</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Slater</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Rohini</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.7445.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2113 8111</institution-id><institution>Division of Cancer, Department of Surgery &#x00026; Cancer, </institution><institution>Imperial College London, Hammersmith Campus, </institution></institution-wrap>Du Cane Road, W120HS, London, UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.16563.37</institution-id><institution-id institution-id-type="ISNI">0000000121663741</institution-id><institution>Department of Translational Medicine, </institution><institution>Universit&#x000e0; del Piemonte Orientale &#x0201c;A. Avogadro&#x0201d;, </institution></institution-wrap>Via Paolo Solaroli, 17, 28100 Novara, NO Italy </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.158820.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2611</institution-id><institution>Department of Biotechnology and Applied Clinical Sciences, </institution><institution>University of L&#x02019;Aquila, </institution></institution-wrap>Via Vetoio, 67100 L&#x02019;Aquila, Italy </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.413629.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0705 4923</institution-id><institution>NIHR Imperial CRF, Imperial College London, </institution><institution>Hammersmith Hospital, </institution></institution-wrap>Du Cane Road, W120HS, London, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.413629.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0705 4923</institution-id><institution>Division of Surgery, Department of Surgery &#x00026; Cancer, Imperial College London, </institution><institution>Hammersmith Hospital, </institution></institution-wrap>Du Cane Road, W120HS, London, UK </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.5475.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0407 4824</institution-id><institution>Faculty of Health and Medical Sciences, </institution><institution>University of Surrey and Department of Oncology, The Royal Surrey Hospital, </institution></institution-wrap>Egerton Rd, Guildford, GU2 7XX UK </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.413629.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0705 4923</institution-id><institution>Department of Radiology, Imperial College NHS Trust, </institution><institution>Hammersmith Hospital, </institution></institution-wrap>Du Cane Road, W120HS, London, UK </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.416041.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0738 5466</institution-id><institution>Barts and The London HPB Centre, </institution><institution>The Royal London Hospital, Barts Health NHS Trust, </institution></institution-wrap>London, UK </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.4868.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 1133</institution-id><institution>Centre for Tumour Biology, </institution><institution>Barts Cancer Institute, Queen Mary University of London, </institution></institution-wrap>London, UK </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.139534.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0372 5777</institution-id><institution>Department of Medical Oncology, </institution><institution>Barts Health NHS Trust, </institution></institution-wrap>London, UK </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>21</volume><elocation-id>301</elocation-id><history><date date-type="received"><day>28</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">After liver resection (LR), patients with hepatocellular cancer (HCC) are at high risk of recurrence. There are no approved anti-cancer therapies known to affect such risk, highlighting the acute need for novel systemic therapies to control the probability of disease relapse. Immunotherapy is expanding as a novel treatment option for HCC. Emerging data from cohort 4 of the CA209&#x02013;040 study, which investigated the safety and preliminary efficacy of nivolumab/ipilimumab co-administration in advanced HCC, suggest that the combination can be delivered safely with an acceptable proportion of reversible grade 3&#x02013;4 toxicities (27.1%) and a low discontinuation rate (2%) in patients with HCC. Here, we describe the design and rationale of PRIME-HCC, a two-part, multi-centre, phase Ib study to assess safety and bioactivity of the nivolumab/ipilimumab combination prior to LR in early-stage HCC.</p></sec><sec><title>Methods</title><p id="Par2">The study involves an initial safety run-in phase (Part 1) to allow for preliminary safety characterisation within the first 6 patients enrolled and a subsequent expansion (Part 2). Ipilimumab will be administered once only on Day 1. Nivolumab will be administered on Day 1 and Day 22 (&#x000b1; 3&#x02009;days) for a total of two 21-day&#x02009;cycles (i.e. 6&#x02009;weeks of treatment). The primary objective of the study is to determine the safety and tolerability of the nivolumab/ipilimumab combination prior to LR. The secondary objective is to preliminarily characterize the efficacy of the combination prior to LR, including objective response rate (ORR) and pathologic response rates. Additional exploratory objectives include preliminary evidence of long-term disease control and to identify predictive correlates of response to the nivolumab/ipilimumab combination in HCC.</p></sec><sec><title>Discussion</title><p id="Par3">The results of this study will help define the positioning of neoadjuvant nivolumab/ipilimumab combination in the perioperative management of HCC, with potential to improve survival outcomes in this patient population.</p></sec><sec><title>Trial registration</title><p id="Par4">EudraCT Number: 2018&#x02013;000987-27 Clinical trial registry &#x00026; ID: <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link>: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03682276">NCT03682276</ext-link>.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12885-021-08033-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HCC</kwd><kwd>Immunotherapy</kwd><kwd>PD-1</kwd><kwd>PD-L1</kwd><kwd>CTLA-4</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100002491</institution-id><institution>Bristol-Myers Squibb</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par30">Hepatocellular carcinoma (HCC) is the sixth commonest and third most lethal solid malignancy on a global scale [<xref ref-type="bibr" rid="CR1">1</xref>]. In spite of the major diagnostic advancements, only one out of three of the newly diagnosed patients are eligible for radical treatments upfront [<xref ref-type="bibr" rid="CR2">2</xref>]. In patients within the Barcelona Clinic Liver Cancer (BCLC) stage 0 or A criteria, surgical resection can be carried out safely with curative intent [<xref ref-type="bibr" rid="CR3">3</xref>]. However, this is only feasible in &#x0003c;&#x02009;30% of the patients, mainly due to the extent of radiological spread of the disease or poor synthetic function due to underlying cirrhosis.</p><sec id="Sec2"><title>The evolving landscape of systemic therapy for HCC</title><p id="Par31">Anti-tumour immunotherapy with monoclonal antibodies blocking the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathways are gaining momentum, where immune checkpoint inhibitors directed against these targets either alone or in combination have shown efficacy in HCC. Pembrolizumab has shown initial evidence of disease-modulating activity in a little less than 20% of patients enrolled in Keynote-224 [<xref ref-type="bibr" rid="CR4">4</xref>], but failed to improve OS in Keynote-240, a placebo-controlled phase III trial which investigated pembrolizumab in treatment-experienced patients with advanced HCC [<xref ref-type="bibr" rid="CR5">5</xref>]. CheckMate-040 (CA209&#x02013;040) is the reference, open label, multi-cohort, phase I/II study which evaluated safety and efficacy of nivolumab in advanced HCC patients [<xref ref-type="bibr" rid="CR6">6</xref>]. Despite evidence of anti-tumour activity, the subsequent phase III study CheckMate-459 failed to confirm thedif significant superiority of first-line nivolumab over sorafenib with respect of OS in the advanced disease (HR&#x02009;=&#x02009;0.85, 95% CI: 0.72&#x02013;1.02; <italic>p</italic>&#x000a0;=&#x02009;0.0752) [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par32">Whilst not yet supported by evidence of OS improvement, dual CTLA-4/PD-1 blockade might also be beneficial, given the different and alternative role of the two biologic axes within the cancer immunity cycle, as CTLA-4 is a key driver in downregulation of tumour-antigen presenting cells and in T-regs enhancement, whereas PD-1/PD-L1 mainly impairs the efficiency of the CD8&#x02009;+&#x02009;CTL response. Reliable evidence of synergistic effects from CTLA-4/PD-1 co-inhibition has been observed in clinical trials amongst other tumour types, in melanoma [<xref ref-type="bibr" rid="CR8">8</xref>], renal cell carcinoma [<xref ref-type="bibr" rid="CR9">9</xref>] and NSCLC [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par33">In HCC, safety and preliminary efficacy of 3 alternative schedules of nivolumab and ipilimumab have been investigated within the cohort 4 of Checkmate-040. Pre-treated patients with Child-Pugh class A advanced disease have been randomised to receive either nivolumab 3&#x02009;mg/kg&#x02009;+&#x02009;ipilimumab 1&#x02009;mg/kg or nivolumab 1&#x02009;mg/kg&#x02009;+&#x02009;ipilimumab 3&#x02009;mg/kg or every 3&#x02009;weeks for four doses followed by maintenance nivolumab monotherapy (240&#x02009;mg flat dose biweekly) until disease progression or unacceptable toxicity. The further arm evaluated nivolumab 3&#x02009;mg/kg&#x02009;+&#x02009;ipilimumab 1&#x02009;mg/kg every 6&#x02009;weeks until unacceptable toxicity or disease progression. The incidence of treatment related adverse events (TRAEs) for the whole cohort was 37% with a 5% discontinuation rate. The efficacy analysis showed the nivolumab/ipilimumab combination to achieve an ORR of 31%, which was higher than the ORR (14%) reported with single agent nivolumab in the same study, and led to US Food and Drug Administration approval of the nivolumab/ipilimumab combination in treatment-experienced advanced HCC patients [<xref ref-type="bibr" rid="CR11">11</xref>].</p></sec><sec id="Sec3"><title>Neoadjuvant immunotherapy</title><p id="Par34">The rapidly changing landscape of systemic therapy in HCC, where combination immunotherapy has led to reproducible evidence of disease-modulation, has prompted clinicians to consider the expansion of immunotherapy to the earlier stages of the disease. There is an acute need for highly active systemic anti-cancer treatments as a pre-operative strategy to attempt disease down-staging and expand the proportion of patients who might benefit from curative surgery. Furthermore, despite optimal local control of the disease, the majority of patients recur within 2&#x02009;years of surgery as a likely result of proliferation of microscopic neoplastic foci within the residual organ, and the 5-year survival rate for early-stage HCC ranges between 17 to 53%, with a recurrence rat that can reach 70% also in the curative resection setting [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. The negative impact on survival secondary to both early and late recurrence of HCC suggests the need for an optimal integration of systemic anti-cancer therapies to control the risk of relapse and increase the chances of cure in patients with early stage HCC.</p><p id="Par35">Currently, there is no standard of care for adjuvant/neoadjuvant treatment and although a number of approaches have been attempted including trans-arterial chemoembolization (TACE), Yttrium-90 radioembolization, and neoadjuvant sorafenib in HCC patients on waiting list for liver transplantation [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Failure to control micro-metastatic disease is a major determinant influencing early relapse and mortality following curative resection and randomized controlled trials have shown sorafenib, to be ineffective in improving outcomes in the adjuvant setting [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par36">Here, we describe the design and the rationale of PRIME-HCC, a two-part multi-centre phase Ib study to assess safety and bioactivity of the nivolumab and ipilimumab combination before LR in patients with HCC.</p></sec></sec><sec id="Sec4"><title>Methods/design</title><p id="Par37">PRIME HCC is a two-part, phase Ib study of ipilimumab and nivolumab combination prior to LR in adult patients (aged &#x02265;18&#x02009;years) with HCC. Ipilimumab will be administered once only on Day 1. Nivolumab will be administered on Day 1 and Day 22 (&#x000b1; 3&#x02009;days) for a total of two 21-day&#x02009;cycles (i.e. 6&#x02009;weeks of treatment). Part 1 of the study will initially consist of a safety run-in phase of 6 participants. If two or fewer surgical delays are observed, the study will continue to Part 2, which will consist of an expansion phase including up to 26 participants. All participants entered into the study will receive nivolumab and ipilimumab for a fixed duration of 6&#x02009;weeks of treatment. The study flow-chart is summarized in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref><bold>.</bold>
<fig id="Fig1"><label>Fig. 1</label><caption><p>PRIME-HCC study objectives and timeline (original figure, no copyright permission required; Created with <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">BioRender.com</ext-link>)</p></caption><graphic xlink:href="12885_2021_8033_Fig1_HTML" id="MO1"/></fig></p><p id="Par38">Ipilimumab is a fully human monoclonal immunoglobulin (Ig) G1k specific for human CTLA-4 manufactured by Bristol Myers Squibb (BMS). Nivolumab is a human monoclonal antibody (HuMAb; immunoglobulin G4 [IgG4]-S228P) manufactured by BMS that inhibits the PD-1 receptor on cell surface. The clinical safety profile of nivolumab and ipilimumab as a combination therapy has emerged from a number of clinical studies in a number of tumour types [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par39">In PRIME-HCC the dosing schedule adopted is 1&#x02009;mg/kg dose Q6W for ipilimumab in combination with nivolumab 3&#x02009;mg/kg Q3W for a total of 2&#x02009;cycles. The rationale for dose selection stems from the clinical experience in the use of the combination across a number of indications. In the specific setting of HCC, whilst there is currently no clinical data available to illustrate the safety and tolerability of the planned regimen administered sequentially with LR, similar dosing schedules including a six-weekly dosing of ipilimumab at 1&#x02009;mg/kg and three-weekly dosing of nivolumab at 3&#x02009;mg/kg have been explored in CA209&#x02013;040 cohort 4. Extrapolating from CA209&#x02013;040 safety data, ipilimumab dose intensity appears to be the strongest determinant of toxicity, in particular with regards to immune-related liver TRAEs: study treatment in Arms B and C, where ipilimumab dose intensitiy was lower, was shown to be better tolerable compared to more intense ipilimumab dosing schedules (3&#x02009;mg/kg in Arm A). For this reason, PRIME-HCC will utilise the lowest effective dose intensity schedule (1&#x02009;mg/kg Q6W) and combine it with nivolumab at the clinically approved dose of 3&#x02009;mg/kg Q3W. The choice of this combination will maintain individual exposures that are optimally consistent with those associated with maximal efficacy response in other indications and that are tolerated and safe, especially considering liver-related TRAEs in a patient population where cirrhosis and concomitant chronic viral infection is highly prevalent.</p><sec id="Sec5"><title>Eligibility criteria</title><p id="Par40">Detailed eligibility criteria are provided in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref><bold>.</bold> In brief, PRIME-HCC will recruit patients amenable to resection and ineligible for liver transplantation, with a confirmed diagnosis of HCC by biopsy or by non-invasive diagnostic criteria of the American Association for the Study of the Liver (AASLD).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Eligibility criteria of PRIME-HCC trial</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Key inclusion criteria</th><th>Key exclusion criteria</th></tr></thead><tbody><tr><td><p>1. Written informed consent for the trial</p><p>2. Aged &#x02265;18&#x02009;years</p><p>3. Confirmed diagnosis of HCC</p><p>4. Willing to provide tissue from an excisional biopsy of a tumour lesion</p><p>5. Have measurable disease by CT-scan or MRI defined by RECIST 1.1 criteria</p><p>6. Ineligible for liver transplantation</p><p>7. Medically fit to undergo surgery as determined by the treating medical and surgical oncology team.</p><p>8. ECOG-PS 0 or 1</p><p>9. Adequate hematologic function, defined as WBC&#x02009;&#x02265;&#x02009;2000/&#x003bc;l, ANC&#x02009;&#x02265;&#x02009;1500/&#x003bc;l, platelet count &#x02265;50,000/&#x003bc;l and hemoglobin &#x02265;8.5&#x02009;g/dl without transfusion or Erythropoietin dependency.</p><p>10. Adequate renal function, defined as creatinine &#x02264;1.5&#x000d7; ULN or measured or calculated creatinine clearance &#x02265;40&#x02009;ml/min for those with creatinine levels &#x0003e;&#x02009;1.5&#x000d7; ULN</p><p>11. Adequate hepatic function, defined as total bilirubin &#x02264;1.5&#x000d7; ULN, and ALT/AST levels &#x02264;5&#x000d7; ULN, albumin &#x02265;2.8&#x02009;g/dL</p><p>12. Adequate coagulation function, defined as INR&#x02009;&#x02264;&#x02009;1.5&#x000d7; ULN unless the patient is receiving anticoagulant therapy as long as PT or aPTT is within the therapeutic range</p><p>10. Overall Child-Pugh class A</p><p>11. Female patient of childbearing potential should have a negative serum pregnancy test within 24&#x02009;h of her first dose of IMP</p><p>12. Women of childbearing potential must be willing to use a highly effective method of contraception</p><p>13. Sexually active males must agree to use an adequate method of contraception</p></td><td><p>1. Extrahepatic metastasis</p><p>2. Prior systemic anticancer treatment for HCC, including an anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody</p><p>3. Prior orthotopic liver transplantation</p><p>4. Any major surgery within the 3&#x02009;weeks prior to enrolment</p><p>5. Hepatic encephalopathy</p><p>6. Ascites that is refractory to diuretic therapy</p><p>7. Is currently receiving anti-cancer therapy (chemotherapy, radiation therapy, immunotherapy or biologic therapy) or has participated or is participating in a study with Nivolumab or Ipilimumab or used an investigational device within 4&#x02009;weeks of the first dose of IMP</p><p>8. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy</p><p>9. Known history of active Bacillus Tuberculosis</p><p>10. History of known hypersensitivity to any monoclonal antibody or any of their excipients</p><p>11. Known additional malignancy that is progressing or requires active treatment <sup>a</sup></p><p>12. Active autoimmune disease that has required systemic treatment in the past 2&#x02009;years <sup>b</sup></p><p>13. Known history of, or any evidence of active, non-infectious pneumonitis</p><p>14. Active infection requiring systemic therapy <sup>c</sup></p><p>15. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial</p><p>16. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial</p><p>17. Pregnant or breastfeeding</p><p>18. Known history of Human Immunodeficiency Virus (HIV; HIV 1/2 antibodies)</p><p>19. Received a live vaccine within 30&#x02009;days of first dose of IMP</p></td></tr></tbody></table><table-wrap-foot><p><italic>CT</italic> Computed tomography; <italic>MRI</italic> Magnetic resonance imaging; <italic>ECOG-PS</italic> Eastern cooperative oncology group-performance status; <italic>WBC</italic> White blood cells; <italic>ANC</italic> Absolute neutrophil count; <italic>ULN</italic> Upper limit of normal; <italic>ALT/AST</italic> Alanine/aspartate aminotransferase; <italic>IMP</italic> Investigational medicinal product; <italic>PTT/PT</italic> Partial thromboplastin time/prombin time; <sup>a</sup> Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer; <sup>b</sup>replacement therapy (eg. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment; <sup>c</sup> with the exceptions relating to Hepatitis B and C virus</p></table-wrap-foot></table-wrap></p><p id="Par41">Participants will require a full hepatitis serology screen prior to enrolment into the study, this includes Hepatitis B and Hepatitis C Virus serology. In patients with positive serology for either virus, baseline HBV DNA and HCV quantitative RNA levels will be requested. Participants who are confirmed to have chronic and active hepatitis B and/or C (i.e. with detectable HBV DNA or HCV RNA at baseline) will have their viral load (HCV RNA and/or HBV DNA as appropriate) monitored at each cycle and at the end of treatment follow-up visit.</p></sec><sec id="Sec6"><title>Planned sample size and study period</title><p id="Par42">We designed the study as a safety-oriented trial and considered enrolling a cohort of up to 32 participants to:
<list list-type="order"><list-item><p id="Par43">Comprehensively characterise the safety profile of nivolumab and ipilimumab co-administration in patients with early-stage HCC;</p></list-item><list-item><p id="Par44">Preliminarily document the efficacy of treatment to inform subsequent efficacy-testing in a future adequately powered trial;</p></list-item><list-item><p id="Par45">Obtain adequate information regarding the disease-modulating effects from treatment reflected by the proposed exploratory endpoints.</p></list-item></list></p><p id="Par46">With the primary endpoint being safety, no power calculation for hypothesis testing is required to formally power the study: the upper 95% confidence interval for toxicity events will inform the decision to proceed to a future, adequately powered, phase II trial. Part 1 of the study will initially require a total of 6 patients. If &#x02264;2 surgical. Delays are observed (primary safety endpoint), the study will continue to Part 2 following Independent Safety Data Monitoring Committee review of preliminary safety data. A second interim analysis will be performed when 100% of the recruited patients have completed study follow-up visit 2 (FU2) to evaluate general safety and tolerability of the combination.</p></sec><sec id="Sec7"><title>Study procedures</title><p id="Par47">Patients will undergo baseline tumour imaging including computed tomography (CT) scan of the chest, abdomen and pelvis, and by contrast enhanced magnetic resonance imaging (MRI) scan of the liver at screening. At post-treatment time-points prior to surgery (on Day 43), after surgery (on Day 127) and 4-monthly thereafter, tumour imaging will be repeated using contrast enhanced MRI. A triple-phase CT of the liver is an acceptable alternative for intrahepatic staging in patients with contraindications to MRI. Baseline CT/MRI scans do not need to be repeated if obtained within 35&#x02009;days of first dose. The same method used for assessment at baseline must then be used at all subsequent time points. RECIST v1.1 criteria will be used to determine patient response to treatment, progression-free survival (PFS) and ORR. A baseline core tumor biopsy will be collected from participants at screening and patients will have a parcel of leftover tissue from their LR specimen stored for correlative studies. Treatment will consist of a maximum of 2&#x02009;cycles of nivolumab 3&#x02009;mg/kg and 1&#x02009;cycle of ipilimumab 1&#x02009;mg/kg administered intravenously Q3W. Patients will be reviewed following completion of IMP treatment (Follow-up visit 1; FU1) on Day 43 +/&#x02212; 3, prior to surgery. LR will be performed as per standard of care. The safety FU2 will be conducted 126&#x02009;days (&#x000b1; 7&#x02009;days) after the first dose of the investigational medicinal product (IMP). All AEs that occur prior to the visit will be recorded. Participants with on-going AEs at the visit will be followed up by principal investigator (PI) or delegate until resolution or stabilisation of the event. Following FU2, participants will be assessed every 4&#x02009;months (&#x000b1; 7&#x02009;days) thereafter to collect information regarding disease status and survival. Long-term follow-up will continue, for each patient, for a total of 2&#x02009;years. The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) schedule of enrolment, interventions, and assessments is provided in Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref><bold>.</bold></p></sec><sec id="Sec8"><title>Outcome measures and endpoints</title><p id="Par48">Primary study endpoints include rate of patients experiencing a surgery delay to Day 89 or later and determination of safety and tolerability of the nivolumab/ipilimumab combination based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 criteria from nivolumab and ipilimumab initiation to 126&#x02009;days later.</p><p id="Par49">Secondary endpoints include ORR on pre-resection imaging at day 42 according to the RECIST v1.1 criteria and pathologic response rate on evaluation of the resected specimen. Exploratory endpoints are PFS rate and OS at day 126 and every 4&#x02009;months thereafter and identity of biomarkers of response to nivolumab and ipilimumab using high-throughput technologies.</p></sec><sec id="Sec9"><title>Adverse events management and dose modifications</title><p id="Par50">Adverse events (both non-serious and serious) of unknown aetiology, associated with IMP exposure and likely to have an immune-mediated underlying mechanism may be considered as irAEs. These AEs may occur from soon after the first dose to months after the last dose. If an irAE is suspected, efforts will be put in place to exclude any other etiologic causes prior to labelling an AE as an irAEs. Summaries of recommendations to managing irAEs and of the physician&#x02019;s guidelines for IMP&#x02019;s temporary interruption and permanent discontinuation in case of toxicities are provided in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref><bold>,</bold> respectively<bold>.</bold> Treatment discontinuation for AST, ALT deterioration in participants who present with Grade 2 AST or ALT at Cycle 1&#x02009;Day 1 will be triggered only if ALT or AST increase by more than or equal to 50% compared to the measurement taken at initiation of systemic treatment (Cycle 1&#x02009;Day 1) and lasts for at least 1&#x02009;week. In addition to the guidelines, dosing should be permanently discontinued in any participant who does not receive the Cycle 2 dose within the allowed window (Day 18 to Day 24) due to being unfit for dosing for any reason.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary of recommendations to managing immune-related adverse events. IrAEs: immune-related adverse events; IMP: investigational medicinal product</p></caption><table frame="hsides" rules="groups"><thead><tr><th>irAE</th><th>Supportive Care Intervention</th></tr></thead><tbody><tr><td>Grade 1</td><td>Provide symptomatic treatment</td></tr><tr><td>Grade 2</td><td><p>Consider systemic corticosteroids in addition to appropriate symptomatic treatment.</p><p>Steroid taper should be considered once symptoms improve to Grade 1 or less and tapered over at least 4&#x02009;weeks.</p></td></tr><tr><td>Grade 3 and Grade 4</td><td><p>Systemic corticosteroids are indicated in addition to appropriate symptomatic treatment. May utilize 1 to 2&#x02009;mg/kg prednisone or equivalent per day.</p><p>Steroid taper should be considered once symptoms improve to Grade 1 or less and tapered over at least 4&#x02009;weeks.</p><p>Consider referral to organ-specific specialist (i.e. gastroenterologist, hepatologist, respiratory physician, endocrinologist) for any grade 3&#x02013;4 irAEs, in order to evaluate substitution treatments and immune-modulating agents, such as anti-TNF&#x003b1; of other immune suppressants.</p></td></tr></tbody></table></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Summary of the physicians&#x02019; guidelines for IMP&#x02019;s temporary interruption and permanent discontinuation in case of immune-related adverse events. PI: principal Investigator</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Toxicity</th><th>Hold treatment for grade</th><th>Timing for restarting treatment</th></tr></thead><tbody><tr><td rowspan="2"><p>Diarrhoea/</p><p>Colitis</p></td><td>2&#x02013;3</td><td>Toxicity resolves to Grade 0&#x02013;1</td></tr><tr><td>4</td><td>Permanently discontinue</td></tr><tr><td rowspan="2">AST, ALT, or Increased Bilirubin</td><td>2</td><td>Toxicity resolves to Grade 0&#x02013;1</td></tr><tr><td>3&#x02013;4</td><td>Permanently discontinue (see exception below)<sup>a</sup></td></tr><tr><td>Type 1 diabetes mellitus (if new onset) or Hyperglycaemia</td><td><p>T1DM or</p><p>3&#x02013;4</p></td><td>Hold the IMP for new onset Type 1 diabetes mellitus or Grade 3&#x02013;4 hyperglycemia associated with evidence of beta cell failure</td></tr><tr><td>Hypophysitis</td><td>2&#x02013;4</td><td>Toxicity resolves to Grade 0&#x02013;1. Therapy with IMP can be continued while endocrine replacement therapy is instituted</td></tr><tr><td rowspan="2">Hyperthyroidism</td><td>3</td><td>Toxicity resolves to Grade 0&#x02013;1</td></tr><tr><td>4</td><td>Permanently discontinue</td></tr><tr><td>Hypothyroidism</td><td>N/A</td><td>Therapy with IMP can be continued while thyroid replacement therapy is instituted</td></tr><tr><td rowspan="2">Infusion Reaction</td><td>2<sup>b</sup></td><td>Toxicity resolves to Grade 0&#x02013;1</td></tr><tr><td>3&#x02013;4</td><td>Permanently discontinue</td></tr><tr><td rowspan="2">Pneumonitis</td><td>2</td><td>Toxicity resolves to Grade 0&#x02013;1</td></tr><tr><td>3&#x02013;4</td><td>Permanently discontinue</td></tr><tr><td rowspan="2">Renal Failure or Nephritis</td><td>2</td><td>Toxicity resolves to Grade 0&#x02013;1</td></tr><tr><td>3&#x02013;4</td><td>Permanently discontinue</td></tr><tr><td rowspan="2">All Other Drug-Related Toxicity<sup>c</sup></td><td>3 or Severe</td><td>Toxicity resolves to Grade 0&#x02013;1</td></tr><tr><td>4</td><td>Permanently discontinue</td></tr></tbody></table><table-wrap-foot><p>Note: Permanently discontinue for any severe or Grade 3 drug-related AE that recurs or any life-threatening event</p><p><sup>a</sup> For participants who begin treatment with Grade 2 AST or ALT at Cycle 1&#x02009;Day 1 of treatment, if AST or ALT increases by greater than or equal to 50% relative to baseline and lasts for at least 1&#x02009;week then participants should be discontinued</p><p><sup>b</sup> If symptoms resolve within one hour of stopping IMP infusion, the infusion may be restarted at 50% of the original infusion rate (e.g., from 100&#x02009;mL/hr. to 50&#x02009;mL/hr). Otherwise dosing will be held until symptoms resolve and the participant should be pre-medicated for the next scheduled dose</p><p><sup>c</sup> Participants with intolerable or persistent Grade 2 drug-related AE may hold study medication at PI/delegate discretion</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Statistical analysis</title><p id="Par51">Statistical analyses will include an intent to treat (ITT) analysis including all participants enrolled and a per protocol analysis using all participants who complete the study without major protocol violations. Descriptive analyses will be performed by cross-tabulating relevant predictors (e.g. demographic variables) and endpoints. Appropriate statistical tests will be carried out, such as Fisher&#x02019;s exact test for categorical variables and Wilcoxon tests for continuous variables. Univariable regression analyses will also be performed to estimate regression coefficients and their 95% confidence intervals. Data analysis will occur when the study is complete. Interim analyses of safety data will be conducted at the end of FU1 and at the end of FU2. The comprehensive statistical analysis plan will be finalised prior to the final analysis.</p><p id="Par52">All participants who receive at least one dose of IMP will be included in the safety analysis set. All participants who receive at least one dose of the IMP and undergo disease re-evaluation as per protocol will be included in the efficacy analysis. Due to the exploratory nature of the study with regards to efficacy endpoints, pathologic response rates and RECIST 1.1 response rates will be presented descriptively. The exploratory endpoint of PFS rate will be shown with Kaplan-Meier plots using the full timespan from the start of IMP administration until the date of progression or death from any cause. Proportions of participants who do not progress and who are alive at Day 127 (FU2) and 4-monthly time-points thereafter will also be estimated. For the exploratory endpoints, appropriate descriptive analysis and univariable regression analysis will be conducted.</p></sec><sec id="Sec11"><title>Translational endpoints</title><p id="Par53">Alongside primary clinical endpoints, PRIME-HCC will generate a biorepository of peripheral blood, tissue, stool and urine samples collected at different study timepoints (Supplementary Table&#x000a0;<xref rid="MOESM2" ref-type="media">2</xref>). Tissue samples pre- and post-immunotherapy will undergo multi-colour immune profiling to evaluate the expression of PD ligands and a panel of other immune checkpoints evaluated in co-expression with CD4, CD8, CD20, CD56, CD68 and FoxP3 to verify their immunologic role in relationship to the peri-tumoural infiltrate. Following macro-dissection and total RNA extraction, targeted transcriptomic profiling using the Nanostring PanCancer Immune panel will be used to evaluate enrichment of 770 genes pertaining to 24 immune cell types in pre-and post-treatment tissue samples. Peripheral blood mononuclear cells will be profiled using flow cytometry to differentiate relative abundance T-cytotoxic (CD3<sup>+</sup>/CD8<sup>+</sup>), T-helper (CD3<sup>+</sup>/CD4<sup>+</sup>/CD25<sup>&#x02212;</sup>) and T-reg cells (CD3<sup>+</sup>/CD4<sup>+</sup>/CD25<sup>high</sup>) and downstream transcriptome analysis will decipher the relative functional contribution of individual T-cell subsets in influencing response to ICPI. Lastly, we will perform plasma and urinary metabolic phenotyping and stool metagenomic analysis to evaluate the contribution of the gut microbiota and associated metabolites in influencing response to neoadjuvant ICI therapy.</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par54">PD-1/PD-L1 inhibitors and CTLA-4 inhibitors, either alone or in combination represent a promising peri-operative therapeutic option. A single dose of pre-operative pembrolizumab, can induce near complete pathologic responses in 19% of stage III/IV resectable melanoma patients [<xref ref-type="bibr" rid="CR23">23</xref>]. Preliminary efficacy reports suggest even higher rates of complete pathologic response ranging from 7 to 45% from neoadjuvant nivolumab/ipilimumab therapy [<xref ref-type="bibr" rid="CR24">24</xref>]. In NSCLC, neoadjuvant checkpoint blockade leads to a higher proportion of major pathologic responses compared to chemotherapy [<xref ref-type="bibr" rid="CR25">25</xref>] and the phase II NEOSTAR trial, has shown that treatment with nivolumab/ipilimumab leads to higher major pathological responses (33%) compared to nivolumab (17%) [<xref ref-type="bibr" rid="CR26">26</xref>]. Similar positive results have been seen in non-metastatic muscle-invasive bladder cancer, where two studies have reported complete response rates of 40 and 29% after up to 3 doses of anti-PD-1/PD-L1 monotherapy [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. A recent phase Ib study of sequential nivolumab/ipilimumab followed by surgery reported pathological complete responses in 45% of patients, although 54% of the patients experienced grade 3&#x02013;4 immune-related adverse events (irAEs) [<xref ref-type="bibr" rid="CR29">29</xref>]. Importantly, alongside the efficacy data, no unexpected surgical delays/complications were reported, and the safety profile appeared improved over chemotherapy also in the neoadjuvant setting [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par55">The study of immune-checkpoint inhibitors in the preoperative setting of HCC is an ideal scenario to enable comprehensive evaluation of predictive correlates of response to treatment. Therapeutic expansion of immunotherapy to early stage patients, however, is accompanied by a number of clinical concerns that require to be addressed prospectively. Firstly, from a safety point of view, concurrent liver failure stemming from underlying cirrhosis and active hepatotropic viral infection makes the interaction between immune checkpoint inhibition and surgical resection a clinical scenario deserving comprehensive safety evaluation. Secondly, there is an inherent lack of efficacy data to confirm the sensitivity of early stage, treatment-na&#x000ef;ve HCC patients to immune checkpoint inhibition. This is a highly relevant point in generalizing the efficacy of anti-PD-1/PD-L1 and anti-CTLA-4 agents across all the stages of HCC, especially given that the majority of patients that have been previously recruited to clinical trials of immune checkpoint inhibitors may have had loco-regional therapies (radiofrequency ablation or TACE). These treatments are widely renowned inducers of immunogenic cell death that might have exerted a priming effect on the immune system by facilitating a broader access to otherwise inaccessible neo-epitopes. Confirmation of the bioactivity of nivolumab in combination with ipilimumab in early stage HCC, where the biology of the disease may significantly differ from that of relapsed or advanced disease, is therefore an important research aim to allow optimal allocation of checkpoint blockade in the treatment paradigm of patients with HCC.</p><p id="Par56">Despite optimal surgical control of the disease, patients with HCC are at high risk of recurrence after LR. Currently, there is no standard of care for neoadjuvant therapy, although a number of approaches have been attempted. The study of immune-checkpoint inhibitors in the preoperative setting of HCC is an ideal scenario to enable comprehensive evaluation of predictive correlates of response to anti-PD-1 and anti-CTLA-4 checkpoint inhibitors. The results of this study will help to define the role of neoadjuvant nivolumab/ipilimumab combination in the management of HCC, with potential to improve survival outcomes in this patient population.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec13"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12885_2021_8033_MOESM1_ESM.docx"><caption><p><bold>Additional file 1.</bold>
</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12885_2021_8033_MOESM2_ESM.docx"><caption><p><bold>Additional file 2.</bold>
</p></caption></media></supplementary-material></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>HCC</term><def><p id="Par5">Hepatocellular carcinoma</p></def></def-item><def-item><term>LR</term><def><p id="Par6">Liver resection</p></def></def-item><def-item><term>ORR</term><def><p id="Par7">Objective response rate</p></def></def-item><def-item><term>BCLC</term><def><p id="Par8">Barcelona clinic liver cancer</p></def></def-item><def-item><term>TACE</term><def><p id="Par9">Trans-arterial chemoembolization</p></def></def-item><def-item><term>PD-1</term><def><p id="Par10">Programmed death-1</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par11">Programmed death-ligand 1</p></def></def-item><def-item><term>CTLA-4</term><def><p id="Par12">Cytotoxic T-lymphocyte-associated protein 4</p></def></def-item><def-item><term>PFS</term><def><p id="Par13">Progression free survival</p></def></def-item><def-item><term>OS</term><def><p id="Par14">Overall survival</p></def></def-item><def-item><term>TRAEs</term><def><p id="Par15">Treatment related adverse events</p></def></def-item><def-item><term>NSCLC</term><def><p id="Par16">Non-small cell lung cancer</p></def></def-item><def-item><term>US</term><def><p id="Par17">United States</p></def></def-item><def-item><term>EU</term><def><p id="Par18">European union</p></def></def-item><def-item><term>AASLD</term><def><p id="Par19">American association for the study of the liver</p></def></def-item><def-item><term>IDSMC</term><def><p id="Par20">Independent safety data monitoring committee</p></def></def-item><def-item><term>FU1</term><def><p id="Par21">Follow-up visit 1</p></def></def-item><def-item><term>FU2</term><def><p id="Par22">Follow-up visit 2</p></def></def-item><def-item><term>CT</term><def><p id="Par23">Computed tomography</p></def></def-item><def-item><term>MRI</term><def><p id="Par24">Magnetic resonance imaging</p></def></def-item><def-item><term>SPIRIT</term><def><p id="Par25">Standard protocol items: recommendations for interventional trials</p></def></def-item><def-item><term>IMP</term><def><p id="Par26">Investigational medicinal product</p></def></def-item><def-item><term>NCI CTCAE</term><def><p id="Par27">National cancer institute common terminology criteria for adverse events</p></def></def-item><def-item><term>IrAEs</term><def><p id="Par28">Immune-related adverse events</p></def></def-item><def-item><term>ITT</term><def><p id="Par29">Intent to treat</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>DJP is supported by grant funding from the Wellcome Trust Strategic Fund (PS3416). Infrastructural support for this research was provided by the Cancer Research UK Imperial Centre, the Imperial College Experimental Cancer Medicine Centre (ECMC), the NIHR Imperial Biomedical Research Centre (BRC) and NIHR Imperial Clinical Research Facility. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>All authors contributed to the publication according to the ICMJE guidelines for the authorship (study conception and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision). All authors read and approved the submitted version of the manuscript (and any substantially modified version that involves the author&#x02019;s contribution to the study). Each author has agreed both be personally accountable for the author&#x02019;s contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. DJP: Principal investigator; concept, preparation of trial, writing of protocol and manuscript. AC, AS, TC, MP, NH, DS, MS, TD, PT, RT, CW, HK, VY, SS: Study doctor; contribution to protocol revisions and manuscript. MM: Project manager; coordination of trial set-up, contribution to protocol and manuscript. RS: Co-investigator; contribution to protocol, trial preparations and manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The PRIME-HCC study is sponsored by Imperial College London and funded by Bristol Myers Squibb. The funders contributed and reviewed study design and reviewed the manuscript for accuracy but had no influence on the decision to publish.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethical approval and consent to participate</title><p id="Par57">The study was reviewed and approved by the London South East NHS Ethics Committee, the UK Medicines and Healthcare products Regulatory Agency and the UK Health Research Authority (IRAS ID 244863). The study is performed in compliance with the declaration of Helsinki and the principles of Good Clinical Practice. Signed informed consent is obtained from each patient before study entry.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par58">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par59">DJP received lecture fees from ViiV Healthcare, Bayer Healthcare and travel expenses from Bristol Myers Squibb (BMS) and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, Astra Zeneca; received research funding (to institution) from MSD, BMS. AC received speaker fess and grant consultancies by BMS, MSD, Roche, Astra Zeneca, Novartis and Astellas. TD has research funding from Merck Serono/Pfizer, honorarium/advisory board fees from Bayer, MSD, Sanofi Aventis, Amgen, Servier and Everything Genetic. PT received consultancy fees from SIRTEX medical. RS received research funding from Incyte, AAA, Astex, Bayer AG; consulting and advisory role: Eisai, Roche, Bayer Healthcare, SIRTEX; lecture fees: Bayer Healthcare, Falk Foundation.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name></person-group><article-title>Global cancer statistics, 2002</article-title><source>CA Cancer J Clin</source><year>2005</year><volume>55</volume><issue>2</issue><fpage>74</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.3322/canjclin.55.2.74</pub-id><?supplied-pmid 15761078?><pub-id pub-id-type="pmid">15761078</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ercolani</surname><given-names>G</given-names></name><name><surname>Grazi</surname><given-names>GL</given-names></name><name><surname>Ravaioli</surname><given-names>M</given-names></name><name><surname>del Gaudio</surname><given-names>M</given-names></name><name><surname>Gardini</surname><given-names>A</given-names></name><name><surname>Cescon</surname><given-names>M</given-names></name><name><surname>Varotti</surname><given-names>G</given-names></name><name><surname>Cetta</surname><given-names>F</given-names></name><name><surname>Cavallari</surname><given-names>A</given-names></name></person-group><article-title>Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence</article-title><source>Ann Surg</source><year>2003</year><volume>237</volume><issue>4</issue><fpage>536</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1097/01.SLA.0000059988.22416.F2</pub-id><?supplied-pmid 1514472?><pub-id pub-id-type="pmid">12677151</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Sherman</surname><given-names>M</given-names></name></person-group><article-title>Practice guidelines committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma</article-title><source>Hepatology</source><year>2005</year><volume>42</volume><issue>5</issue><fpage>1208</fpage><lpage>1236</lpage><pub-id pub-id-type="doi">10.1002/hep.20933</pub-id><?supplied-pmid 16250051?><pub-id pub-id-type="pmid">16250051</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>AX</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Edeline</surname><given-names>J</given-names></name><name><surname>Cattan</surname><given-names>S</given-names></name><name><surname>Ogasawara</surname><given-names>S</given-names></name><name><surname>Palmer</surname><given-names>D</given-names></name><name><surname>Verslype</surname><given-names>C</given-names></name><name><surname>Zagonel</surname><given-names>V</given-names></name><name><surname>Fartoux</surname><given-names>L</given-names></name><name><surname>Vogel</surname><given-names>A</given-names></name><name><surname>Sarker</surname><given-names>D</given-names></name><name><surname>Verset</surname><given-names>G</given-names></name><name><surname>Chan</surname><given-names>SL</given-names></name><name><surname>Knox</surname><given-names>J</given-names></name><name><surname>Daniele</surname><given-names>B</given-names></name><name><surname>Webber</surname><given-names>AL</given-names></name><name><surname>Ebbinghaus</surname><given-names>SW</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>AB</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Alistar</surname><given-names>A</given-names></name><name><surname>Asselah</surname><given-names>J</given-names></name><name><surname>Blanc</surname><given-names>JF</given-names></name><name><surname>Borbath</surname><given-names>I</given-names></name><name><surname>Cannon</surname><given-names>T</given-names></name><name><surname>Chung</surname><given-names>K</given-names></name><name><surname>Cohn</surname><given-names>A</given-names></name><name><surname>Cosgrove</surname><given-names>DP</given-names></name><name><surname>Damjanov</surname><given-names>N</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Karino</surname><given-names>Y</given-names></name><name><surname>Karwal</surname><given-names>M</given-names></name><name><surname>Kaubisch</surname><given-names>A</given-names></name><name><surname>Kelley</surname><given-names>R</given-names></name><name><surname>van Laethem</surname><given-names>JL</given-names></name><name><surname>Larson</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Manhas</surname><given-names>A</given-names></name><name><surname>Manji</surname><given-names>GA</given-names></name><name><surname>Numata</surname><given-names>K</given-names></name><name><surname>Parsons</surname><given-names>B</given-names></name><name><surname>Paulson</surname><given-names>AS</given-names></name><name><surname>Pinto</surname><given-names>C</given-names></name><name><surname>Ramirez</surname><given-names>R</given-names></name><name><surname>Ratnam</surname><given-names>S</given-names></name><name><surname>Rizell</surname><given-names>M</given-names></name><name><surname>Rosmorduc</surname><given-names>O</given-names></name><name><surname>Sada</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Stal</surname><given-names>PI</given-names></name><name><surname>Strasser</surname><given-names>S</given-names></name><name><surname>Trojan</surname><given-names>J</given-names></name><name><surname>Vaccaro</surname><given-names>G</given-names></name><name><surname>van Vlierberghe</surname><given-names>H</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>KH</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name></person-group><article-title>Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial</article-title><source>Lancet Oncol</source><year>2018</year><volume>19</volume><issue>7</issue><fpage>940</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(18)30351-6</pub-id><?supplied-pmid 29875066?><pub-id pub-id-type="pmid">29875066</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Ryoo</surname><given-names>BY</given-names></name><name><surname>Merle</surname><given-names>P</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Bouattour</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Breder</surname><given-names>V</given-names></name><name><surname>Edeline</surname><given-names>J</given-names></name><name><surname>Chao</surname><given-names>Y</given-names></name><name><surname>Ogasawara</surname><given-names>S</given-names></name><name><surname>Yau</surname><given-names>T</given-names></name><name><surname>Garrido</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>SL</given-names></name><name><surname>Knox</surname><given-names>J</given-names></name><name><surname>Daniele</surname><given-names>B</given-names></name><name><surname>Ebbinghaus</surname><given-names>SW</given-names></name><name><surname>Chen</surname><given-names>E</given-names></name><name><surname>Siegel</surname><given-names>AB</given-names></name><name><surname>Zhu</surname><given-names>AX</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name><collab>on behalf of the KEYNOTE-240 investigators</collab></person-group><article-title>Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><issue>3</issue><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.01307</pub-id><?supplied-pmid 31790344?><pub-id pub-id-type="pmid">31790344</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Khoueiry</surname><given-names>AB</given-names></name><name><surname>Sangro</surname><given-names>B</given-names></name><name><surname>Yau</surname><given-names>T</given-names></name><name><surname>Crocenzi</surname><given-names>TS</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Hsu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial</article-title><source>Lancet</source><year>2017</year><volume>389</volume><issue>10088</issue><fpage>2492</fpage><lpage>2502</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31046-2</pub-id><?supplied-pmid 28434648?><pub-id pub-id-type="pmid">28434648</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yau</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Cheng</surname><given-names>A-L</given-names></name><name><surname>Mathurin</surname><given-names>P</given-names></name><name><surname>Edeline</surname><given-names>J</given-names></name><etal/></person-group><article-title>LBA38_PRCheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)</article-title><source>Ann Oncol</source><year>2019</year><volume>30</volume><issue>suppl_5</issue><fpage>v851</fpage><lpage>v934</lpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Chiarion-Sileni</surname><given-names>V</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Grob</surname><given-names>JJ</given-names></name><name><surname>Rutkowski</surname><given-names>P</given-names></name><name><surname>Lao</surname><given-names>CD</given-names></name><name><surname>Cowey</surname><given-names>CL</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Wagstaff</surname><given-names>J</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Ferrucci</surname><given-names>PF</given-names></name><name><surname>Smylie</surname><given-names>M</given-names></name><name><surname>Hogg</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>M&#x000e1;rquez-Rodas</surname><given-names>I</given-names></name><name><surname>Haanen</surname><given-names>J</given-names></name><name><surname>Guidoboni</surname><given-names>M</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Sch&#x000f6;ffski</surname><given-names>P</given-names></name><name><surname>Carlino</surname><given-names>MS</given-names></name><name><surname>Lebb&#x000e9;</surname><given-names>C</given-names></name><name><surname>McArthur</surname><given-names>G</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Daniels</surname><given-names>GA</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Bastholt</surname><given-names>L</given-names></name><name><surname>Rizzo</surname><given-names>JI</given-names></name><name><surname>Balogh</surname><given-names>A</given-names></name><name><surname>Moshyk</surname><given-names>A</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name></person-group><article-title>Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma</article-title><source>N Engl J Med</source><year>2019</year><volume>381</volume><issue>16</issue><fpage>1535</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1910836</pub-id><pub-id pub-id-type="pmid">31562797</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Ar&#x000e9;n Frontera</surname><given-names>O</given-names></name><name><surname>Hammers</surname><given-names>HJ</given-names></name><name><surname>Carducci</surname><given-names>MA</given-names></name><name><surname>Salman</surname><given-names>P</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Beuselinck</surname><given-names>B</given-names></name><name><surname>Amin</surname><given-names>A</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Neiman</surname><given-names>V</given-names></name><name><surname>Bracarda</surname><given-names>S</given-names></name><name><surname>Tykodi</surname><given-names>SS</given-names></name><name><surname>Barth&#x000e9;l&#x000e9;my</surname><given-names>P</given-names></name><name><surname>Leibowitz-Amit</surname><given-names>R</given-names></name><name><surname>Plimack</surname><given-names>ER</given-names></name><name><surname>Oosting</surname><given-names>SF</given-names></name><name><surname>Redman</surname><given-names>B</given-names></name><name><surname>Melichar</surname><given-names>B</given-names></name><name><surname>Powles</surname><given-names>T</given-names></name><name><surname>Nathan</surname><given-names>P</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Pook</surname><given-names>D</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Donskov</surname><given-names>F</given-names></name><name><surname>Grimm</surname><given-names>MO</given-names></name><name><surname>Gurney</surname><given-names>H</given-names></name><name><surname>Heng</surname><given-names>DYC</given-names></name><name><surname>Kollmannsberger</surname><given-names>CK</given-names></name><name><surname>Harrison</surname><given-names>MR</given-names></name><name><surname>Tomita</surname><given-names>Y</given-names></name><name><surname>Duran</surname><given-names>I</given-names></name><name><surname>Gr&#x000fc;nwald</surname><given-names>V</given-names></name><name><surname>McHenry</surname><given-names>M</given-names></name><name><surname>Mekan</surname><given-names>S</given-names></name><name><surname>Tannir</surname><given-names>NM</given-names></name><collab>CheckMate 214 investigators</collab></person-group><article-title>Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial [published correction appears in lancet Oncol. 2019 Aug 21;:] [published correction appears in lancet Oncol. 2020 Jun;21(6):e304]</article-title><source>Lancet Oncol</source><year>2019</year><volume>20</volume><issue>10</issue><fpage>1370</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30413-9</pub-id><?supplied-pmid 31427204?><pub-id pub-id-type="pmid">31427204</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Paz-Ares</surname><given-names>L</given-names></name><name><surname>Bernabe Caro</surname><given-names>R</given-names></name><name><surname>Zurawski</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Carcereny Costa</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Alexandru</surname><given-names>A</given-names></name><name><surname>Lupinacci</surname><given-names>L</given-names></name><name><surname>de la Mora Jimenez</surname><given-names>E</given-names></name><name><surname>Sakai</surname><given-names>H</given-names></name><name><surname>Albert</surname><given-names>I</given-names></name><name><surname>Vergnenegre</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>S</given-names></name><name><surname>Syrigos</surname><given-names>K</given-names></name><name><surname>Barlesi</surname><given-names>F</given-names></name><name><surname>Reck</surname><given-names>M</given-names></name><name><surname>Borghaei</surname><given-names>H</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>O&#x02019;Byrne</surname><given-names>KJ</given-names></name><name><surname>Geese</surname><given-names>WJ</given-names></name><name><surname>Bhagavatheeswaran</surname><given-names>P</given-names></name><name><surname>Rabindran</surname><given-names>SK</given-names></name><name><surname>Kasinathan</surname><given-names>RS</given-names></name><name><surname>Nathan</surname><given-names>FE</given-names></name><name><surname>Ramalingam</surname><given-names>SS</given-names></name></person-group><article-title>Nivolumab plus Ipilimumab in advanced non-small-cell lung Cancer</article-title><source>N Engl J Med</source><year>2019</year><volume>381</volume><issue>21</issue><fpage>2020</fpage><lpage>2031</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1910231</pub-id><?supplied-pmid 31562796?><pub-id pub-id-type="pmid">31562796</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yau</surname><given-names>T</given-names></name><name><surname>Kang</surname><given-names>Y-K</given-names></name><name><surname>Kim</surname><given-names>T-Y</given-names></name><name><surname>El-Khoueiry</surname><given-names>AB</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Sangro</surname><given-names>B</given-names></name><etal/></person-group><article-title>Nivolumab (NIVO)+ ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><issue>suppl_15</issue><fpage>4012</fpage><pub-id pub-id-type="doi">10.1200/JCO.2019.37.15_suppl.4012</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>XP</given-names></name><name><surname>Qiu</surname><given-names>FZ</given-names></name><name><surname>Wu</surname><given-names>ZD</given-names></name><name><surname>Zhang</surname><given-names>ZW</given-names></name><name><surname>Huang</surname><given-names>ZY</given-names></name><name><surname>Chen</surname><given-names>YF</given-names></name></person-group><article-title>Long-term outcome of resection of large hepatocellular carcinoma</article-title><source>Br J Surg</source><year>2006</year><volume>93</volume><issue>5</issue><fpage>600</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1002/bjs.5335</pub-id><?supplied-pmid 16607679?><pub-id pub-id-type="pmid">16607679</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>WH</given-names></name><name><surname>Hwang</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>GW</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Ahn</surname><given-names>CS</given-names></name><name><surname>Moon</surname><given-names>DB</given-names></name><name><surname>Jung</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>GC</given-names></name><name><surname>Lee</surname><given-names>SG</given-names></name></person-group><article-title>Prognostic effect of transarterial chemoembolization-induced complete pathological response in patients undergoing liver resection and transplantation for hepatocellular carcinoma</article-title><source>Liver Transpl</source><year>2017</year><volume>23</volume><issue>6</issue><fpage>781</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1002/lt.24752</pub-id><?supplied-pmid 28240808?><pub-id pub-id-type="pmid">28240808</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toso</surname><given-names>C</given-names></name><name><surname>Mentha</surname><given-names>G</given-names></name><name><surname>Kneteman</surname><given-names>NM</given-names></name><name><surname>Majno</surname><given-names>P</given-names></name></person-group><article-title>The place of downstaging for hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2010</year><volume>52</volume><issue>6</issue><fpage>930</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2009.12.032</pub-id><?supplied-pmid 20385428?><pub-id pub-id-type="pmid">20385428</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>K</given-names></name><name><surname>Ganten</surname><given-names>T</given-names></name><name><surname>Gotthardtp</surname><given-names>D</given-names></name><name><surname>Radeleff</surname><given-names>B</given-names></name><name><surname>Settmacher</surname><given-names>U</given-names></name><name><surname>Kollmar</surname><given-names>O</given-names></name><name><surname>Nadalin</surname><given-names>S</given-names></name><name><surname>Karapanagiotou-Schenkel</surname><given-names>I</given-names></name><name><surname>von Kalle</surname><given-names>C</given-names></name><name><surname>J&#x000e4;ger</surname><given-names>D</given-names></name><name><surname>B&#x000fc;chler</surname><given-names>MW</given-names></name><name><surname>Schemmer</surname><given-names>P</given-names></name></person-group><article-title>Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial</article-title><source>BMC Cancer</source><year>2015</year><volume>15</volume><fpage>392</fpage><pub-id pub-id-type="doi">10.1186/s12885-015-1373-z</pub-id><?supplied-pmid 25957784?><pub-id pub-id-type="pmid">25957784</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Takayama</surname><given-names>T</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Chau</surname><given-names>GY</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name><name><surname>Han</surname><given-names>KH</given-names></name><name><surname>Tak</surname><given-names>WY</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Song</surname><given-names>T</given-names></name><name><surname>Roayaie</surname><given-names>S</given-names></name><name><surname>Bolondi</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Makuuchi</surname><given-names>M</given-names></name><name><surname>Souza</surname><given-names>F</given-names></name><name><surname>Berre</surname><given-names>MAL</given-names></name><name><surname>Meinhardt</surname><given-names>G</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name></person-group><article-title>Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Oncol</source><year>2015</year><volume>16</volume><issue>13</issue><fpage>1344</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00198-9</pub-id><pub-id pub-id-type="pmid">26361969</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonia</surname><given-names>SJ</given-names></name><name><surname>L&#x000f3;pez-Martin</surname><given-names>JA</given-names></name><name><surname>Bendell</surname><given-names>J</given-names></name><name><surname>Ott</surname><given-names>PA</given-names></name><name><surname>Taylor</surname><given-names>M</given-names></name><name><surname>Eder</surname><given-names>JP</given-names></name><name><surname>J&#x000e4;ger</surname><given-names>D</given-names></name><name><surname>Pietanza</surname><given-names>MC</given-names></name><name><surname>le</surname><given-names>DT</given-names></name><name><surname>de Braud</surname><given-names>F</given-names></name><name><surname>Morse</surname><given-names>MA</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Horn</surname><given-names>L</given-names></name><name><surname>Amin</surname><given-names>A</given-names></name><name><surname>Pillai</surname><given-names>RN</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>Chau</surname><given-names>I</given-names></name><name><surname>Bono</surname><given-names>P</given-names></name><name><surname>Atmaca</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Harbison</surname><given-names>CT</given-names></name><name><surname>Lin</surname><given-names>CS</given-names></name><name><surname>Christensen</surname><given-names>O</given-names></name><name><surname>Calvo</surname><given-names>E</given-names></name></person-group><article-title>Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial</article-title><source>Lancet Oncol</source><year>2016</year><volume>17</volume><issue>7</issue><fpage>883</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(16)30098-5</pub-id><?supplied-pmid 27269741?><pub-id pub-id-type="pmid">27269741</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Rizvi</surname><given-names>NA</given-names></name><name><surname>Goldman</surname><given-names>JW</given-names></name><name><surname>Gettinger</surname><given-names>SN</given-names></name><name><surname>Borghaei</surname><given-names>H</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Ready</surname><given-names>NE</given-names></name><name><surname>Gerber</surname><given-names>DE</given-names></name><name><surname>Chow</surname><given-names>LQ</given-names></name><name><surname>Juergens</surname><given-names>RA</given-names></name><name><surname>Shepherd</surname><given-names>FA</given-names></name><name><surname>Laurie</surname><given-names>SA</given-names></name><name><surname>Geese</surname><given-names>WJ</given-names></name><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>TC</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Antonia</surname><given-names>SJ</given-names></name></person-group><article-title>Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study</article-title><source>Lancet Oncol</source><year>2017</year><volume>18</volume><issue>1</issue><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(16)30624-6</pub-id><?supplied-pmid 27932067?><pub-id pub-id-type="pmid">27932067</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammers</surname><given-names>HJ</given-names></name><name><surname>Plimack</surname><given-names>ER</given-names></name><name><surname>Infante</surname><given-names>JR</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Lewis</surname><given-names>LD</given-names></name><name><surname>Voss</surname><given-names>MH</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Pal</surname><given-names>SK</given-names></name><name><surname>Razak</surname><given-names>ARA</given-names></name><name><surname>Kollmannsberger</surname><given-names>C</given-names></name><name><surname>Heng</surname><given-names>DYC</given-names></name><name><surname>Spratlin</surname><given-names>J</given-names></name><name><surname>McHenry</surname><given-names>MB</given-names></name><name><surname>Amin</surname><given-names>A</given-names></name></person-group><article-title>Safety and efficacy of Nivolumab in combination with Ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><issue>34</issue><fpage>3851</fpage><lpage>3858</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.72.1985</pub-id><?supplied-pmid 28678668?><pub-id pub-id-type="pmid">28678668</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janjigian</surname><given-names>YY</given-names></name><name><surname>Bendell</surname><given-names>J</given-names></name><name><surname>Calvo</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Ott</surname><given-names>PA</given-names></name><name><surname>Peltola</surname><given-names>K</given-names></name><name><surname>Jaeger</surname><given-names>D</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>de Braud</surname><given-names>F</given-names></name><name><surname>Chau</surname><given-names>I</given-names></name><name><surname>Harbison</surname><given-names>CT</given-names></name><name><surname>Dorange</surname><given-names>C</given-names></name><name><surname>Tschaika</surname><given-names>M</given-names></name><name><surname>le</surname><given-names>DT</given-names></name></person-group><article-title>CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer [published correction appears in J Clin Oncol. 2019 Feb 10;37(5):443]</article-title><source>J Clin Oncol</source><year>2018</year><volume>36</volume><issue>28</issue><fpage>2836</fpage><lpage>2844</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.76.6212</pub-id><?supplied-pmid 30110194?><pub-id pub-id-type="pmid">30110194</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morse</surname><given-names>MA</given-names></name><name><surname>Overman</surname><given-names>MJ</given-names></name><name><surname>Hartman</surname><given-names>L</given-names></name><name><surname>Khoukaz</surname><given-names>T</given-names></name><name><surname>Brutcher</surname><given-names>E</given-names></name><name><surname>Lenz</surname><given-names>HJ</given-names></name><name><surname>Atasoy</surname><given-names>A</given-names></name><name><surname>Shangguan</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>el-Rayes</surname><given-names>B</given-names></name></person-group><article-title>Safety of Nivolumab plus low-dose Ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal Cancer</article-title><source>Oncologist.</source><year>2019</year><volume>24</volume><issue>11</issue><fpage>1453</fpage><lpage>1461</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2019-0129</pub-id><?supplied-pmid 31147488?><pub-id pub-id-type="pmid">31147488</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omuro</surname><given-names>A</given-names></name><name><surname>Vlahovic</surname><given-names>G</given-names></name><name><surname>Lim</surname><given-names>M</given-names></name><name><surname>Sahebjam</surname><given-names>S</given-names></name><name><surname>Baehring</surname><given-names>J</given-names></name><name><surname>Cloughesy</surname><given-names>T</given-names></name><name><surname>Voloschin</surname><given-names>A</given-names></name><name><surname>Ramkissoon</surname><given-names>SH</given-names></name><name><surname>Ligon</surname><given-names>KL</given-names></name><name><surname>Latek</surname><given-names>R</given-names></name><name><surname>Zwirtes</surname><given-names>R</given-names></name><name><surname>Strauss</surname><given-names>L</given-names></name><name><surname>Paliwal</surname><given-names>P</given-names></name><name><surname>Harbison</surname><given-names>CT</given-names></name><name><surname>Reardon</surname><given-names>DA</given-names></name><name><surname>Sampson</surname><given-names>JH</given-names></name></person-group><article-title>Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143</article-title><source>Neuro-Oncology</source><year>2018</year><volume>20</volume><issue>5</issue><fpage>674</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nox208</pub-id><?supplied-pmid 29106665?><pub-id pub-id-type="pmid">29106665</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>AC</given-names></name><name><surname>Orlowski</surname><given-names>RJ</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Mick</surname><given-names>R</given-names></name><name><surname>George</surname><given-names>SM</given-names></name><name><surname>Yan</surname><given-names>PK</given-names></name><name><surname>Manne</surname><given-names>S</given-names></name><name><surname>Kraya</surname><given-names>AA</given-names></name><name><surname>Wubbenhorst</surname><given-names>B</given-names></name><name><surname>Dorfman</surname><given-names>L</given-names></name><name><surname>D&#x02019;Andrea</surname><given-names>K</given-names></name><name><surname>Wenz</surname><given-names>BM</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Chilukuri</surname><given-names>L</given-names></name><name><surname>Kozlov</surname><given-names>A</given-names></name><name><surname>Carberry</surname><given-names>M</given-names></name><name><surname>Giles</surname><given-names>L</given-names></name><name><surname>Kier</surname><given-names>MW</given-names></name><name><surname>Quagliarello</surname><given-names>F</given-names></name><name><surname>McGettigan</surname><given-names>S</given-names></name><name><surname>Kreider</surname><given-names>K</given-names></name><name><surname>Annamalai</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Mogg</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Blumenschein</surname><given-names>WM</given-names></name><name><surname>Yearley</surname><given-names>JH</given-names></name><name><surname>Linette</surname><given-names>GP</given-names></name><name><surname>Amaravadi</surname><given-names>RK</given-names></name><name><surname>Schuchter</surname><given-names>LM</given-names></name><name><surname>Herati</surname><given-names>RS</given-names></name><name><surname>Bengsch</surname><given-names>B</given-names></name><name><surname>Nathanson</surname><given-names>KL</given-names></name><name><surname>Farwell</surname><given-names>MD</given-names></name><name><surname>Karakousis</surname><given-names>GC</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Mitchell</surname><given-names>TC</given-names></name></person-group><article-title>A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma</article-title><source>Nat Med</source><year>2019</year><volume>25</volume><issue>3</issue><fpage>454</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0357-y</pub-id><?supplied-pmid 30804515?><pub-id pub-id-type="pmid">30804515</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garutti</surname><given-names>M</given-names></name><name><surname>Buriolla</surname><given-names>S</given-names></name><name><surname>Bertoli</surname><given-names>E</given-names></name><etal/></person-group><article-title>"To Anticipate": neoadjuvant therapy in melanoma with a focus on predictive biomarkers</article-title><source>Cancers (Basel)</source><year>2020</year><volume>12</volume><issue>7</issue><fpage>E1941</fpage><pub-id pub-id-type="doi">10.3390/cancers12071941</pub-id><pub-id pub-id-type="pmid">32708968</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>XH</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Geng</surname><given-names>LY</given-names></name><etal/></person-group><article-title>Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: a meta-analysis [published online ahead of print, 2020 Jul 10]</article-title><source>Lung Cancer</source><year>2020</year><volume>147</volume><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2020.07.001</pub-id><?supplied-pmid 32717571?><pub-id pub-id-type="pmid">32717571</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascone</surname><given-names>T</given-names></name><name><surname>William</surname><given-names>WN</given-names></name><name><surname>Weissferdt</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>HY</given-names></name><name><surname>Leung</surname><given-names>CH</given-names></name><name><surname>Carter</surname><given-names>BW</given-names></name><name><surname>Fossella</surname><given-names>FV</given-names></name><name><surname>Mott</surname><given-names>F</given-names></name><name><surname>Papadimitrakopoulou</surname><given-names>V</given-names></name><name><surname>Blumenschein</surname><given-names>GR</given-names><suffix>Jr</suffix></name><name><surname>le</surname><given-names>X</given-names></name><name><surname>Federico</surname><given-names>L</given-names></name><name><surname>Parra Cuentas</surname><given-names>ER</given-names></name><name><surname>Bernatchez</surname><given-names>C</given-names></name><name><surname>Wistuba</surname><given-names>II</given-names></name><name><surname>Vaporciyan</surname><given-names>AA</given-names></name><name><surname>Gibbons</surname><given-names>DL</given-names></name><name><surname>Swisher</surname><given-names>S</given-names></name><name><surname>Heymach</surname><given-names>J</given-names></name><name><surname>Sepesi</surname><given-names>B</given-names></name><collab>NEOSTAR Study Group</collab></person-group><article-title>Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): clinical and correlative results from the NEOSTAR study</article-title><source>J Clin Oncol</source><year>2019</year><volume>37</volume><issue>15_suppl</issue><fpage>8504</fpage><pub-id pub-id-type="doi">10.1200/JCO.2019.37.15_suppl.8504</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Necchi</surname><given-names>A</given-names></name><name><surname>Anichini</surname><given-names>A</given-names></name><name><surname>Raggi</surname><given-names>D</given-names></name><name><surname>Briganti</surname><given-names>A</given-names></name><name><surname>Massa</surname><given-names>S</given-names></name><name><surname>Lucian&#x000f2;</surname><given-names>R</given-names></name><name><surname>Colecchia</surname><given-names>M</given-names></name><name><surname>Giannatempo</surname><given-names>P</given-names></name><name><surname>Mortarini</surname><given-names>R</given-names></name><name><surname>Bianchi</surname><given-names>M</given-names></name><name><surname>Far&#x000e8;</surname><given-names>E</given-names></name><name><surname>Monopoli</surname><given-names>F</given-names></name><name><surname>Colombo</surname><given-names>R</given-names></name><name><surname>Gallina</surname><given-names>A</given-names></name><name><surname>Salonia</surname><given-names>A</given-names></name><name><surname>Messina</surname><given-names>A</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Madison</surname><given-names>R</given-names></name><name><surname>Ross</surname><given-names>JS</given-names></name><name><surname>Chung</surname><given-names>JH</given-names></name><name><surname>Salvioni</surname><given-names>R</given-names></name><name><surname>Mariani</surname><given-names>L</given-names></name><name><surname>Montorsi</surname><given-names>F</given-names></name></person-group><article-title>Pembrolizumab as Neoadjuvant therapy before radical cystectomy in patients with muscle-invasive Urothelial bladder carcinoma (PURE-01): an open-label, single-arm</article-title><source>Phase II Study J Clin Oncol</source><year>2018</year><volume>36</volume><issue>34</issue><fpage>3353</fpage><lpage>3360</lpage><pub-id pub-id-type="doi">10.1200/JCO.18.01148</pub-id><?supplied-pmid 30343614?><pub-id pub-id-type="pmid">30343614</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Powles T, Rodriguez-Vida A, Duran I et al. A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). J Clin Oncol 36(Suppl.): Abstract 4506.</mixed-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Heijden</surname><given-names>MS</given-names></name><name><surname>van Dijk</surname><given-names>N</given-names></name><name><surname>Smit</surname><given-names>L</given-names></name><etal/></person-group><article-title>Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO)</article-title><source>Ann Oncol</source><year>2019</year><volume>30</volume><issue>suppl_5</issue><fpage>v356</fpage><lpage>v402</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz249</pub-id></element-citation></ref></ref-list></back></article>